Lymphoma vaccine therapy: Next steps after a positive, controlled phase III clinical trial

Seminars in Oncology

Volumn 39, Issue 3, 2012, Pages 253-262

  Thomas, Sheeba K ^a   Kwak, Larry W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; KEYHOLE LIMPET HEMOCYANIN VACCINE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; FEVER; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MYALGIA; PRIORITY JOURNAL; SKIN MANIFESTATION;

ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYMPHOMA, B-CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861126779     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.014     Document Type: Article

References (36)

1. S. Sirisinha, H.N. Eisen Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins Proc Natl Acad Sci U S A 68 1971 3130 3135
2. G.T. Stevenson, E.V. Elliott, F.K. Stevenson Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target Fed Proc 36 1977 2268 2271 (Pubitemid 8138672)
3. G.T. Stevenson, F.K. Stevenson Antibody to a molecularly-defined antigen confined to a tumour cell surface Nature 254 1975 714 716
4. S.H. Bridges Participation of the humoral immune system in the myeloma-specific transplantation resistance J Immunol 121 1978 479 483 (Pubitemid 8397233)
5. M.J. Daley, H.M. Gebel, R.G. Lynch Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy J Immunol 120 1978 1620 1624 (Pubitemid 8400400)
6. A.J. George, A.L. Tutt, F.K. Stevenson Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1 J Immunol 138 1987 628 634 (Pubitemid 17002231)
7. T. Jorgensen, G. Gaudernack, K. Hannestad Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315 Scand J Immunol 11 1980 29 35 (Pubitemid 10146391)
8. M.S. Kaminski, K. Kitamura, D.G. Maloney, R. Levy Idiotype vaccination against murine B cell lymphoma Inhibition of tumor immunity by free idiotype protein J Immunol 138 1987 1289 1296 (Pubitemid 17017921)
9. L.W. Kwak, M.J. Campbell, A.D. Zelenetz, R. Levy Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin Blood 76 1990 2411 2417
10. L.W. Kwak, H.A. Young, R.W. Pennington, S.D. Weeks Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response Proc Natl Acad Sci U S A 93 1996 10972 10977 (Pubitemid 26333102)
11. F.K. Stevenson, J. Gordon Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation J Immunol 130 1983 970 973 (Pubitemid 13186337)
12. S. Sugai, D.W. Palmer, N. Talal, I.P. Witz Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice J Exp Med 140 1974 1547 1558
13. M. Bendandi, C.D. Gocke, C.B. Kobrin Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Nat Med 5 1999 1171 1177 (Pubitemid 29474422)
14. L.W. Kwak, M.J. Campbell, D.K. Czerwinski Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors N Engl J Med 327 1992 1209 1215
15. R.G. Lynch, R.J. Graff, S. Sirisinha Myeloma proteins as tumor-specific transplantation antigens Proc Natl Acad Sci U S A 69 1972 1540
16. P.M. Freedman, J.R. Autry, S. Tokuda, R.C. Williams Jr Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein JNCI 56 1976 735
17. F.J. Hsu, C.B. Caspar, D. Czerwinski Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial Blood 89 1997 3129 3135
18. R. Houot, R. Levy Vaccines for lymphomas: idiotype vaccines and beyond Blood Rev 23 2009 137 142
19. W.K. Weng, D. Czerwinski, J. Timmerman Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype J Clin Oncol 22 2004 4717 4724
20. A.M. Kalergis, J.V. Ravetch Inducing tumor immunity through the selective engagement of activating Fc gamma receptors on dendritic cells J Exp Med 195 2002 1653 1659 (Pubitemid 34666079)
21. J.M. Timmerman, D.K. Czerwinski, T.A. Davis Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 99 2002 1517 1526 (Pubitemid 34533020)
22. A.A. McCormick, S. Reddy, S.J. Reinl Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study Proc Natl Acad Sci U S A 105 2008 10131
23. S. Inoges, M. Rodriguez-Calvillo, N. Zabalegui Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma JNCI 98 2006 1292
24. S.S. Neelapu, L.W. Kwak, C.B. Kobrin Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma Nature Med 11 2005 986 991 (Pubitemid 41294445)
25. S. Baskar, C.B. Kobrin, L.W. Kwak Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes J Clin Invest 113 2004 1498 1510 (Pubitemid 39071706)
26. S. Schuster, S. Neelapu, B.L. Gause Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma J Clin Oncol 29 2011 2787 2794
27. A. Freedman, S.S. Neelapu, C. Nichols Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte- macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma J Clin Oncol 27 2009 3036 3043
28. R.E. Hawkins, D. Zhu, M. Ovecka Idiotypic vaccination against human B-cell lymphoma Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines Blood 83 1994 3279 3288 (Pubitemid 24158474)
29. A.D. Syrengelas, T.T. Chen, R. Levy DNA immunization induces protective immunity against B-cell lymphoma Nat Med 2 1996 1038 1041 (Pubitemid 26306846)
30. A. Biragyn, M. Surenhu, D. Yang Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens J Immunol 167 2001 6644 6653 (Pubitemid 33081603)
31. D. Yang, O. Chertov, S.N. Bykovskaia Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 Science 286 1999 525 528
32. A. Biragyn, P.A. Ruffini, C.A. Leifer Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2 Science 298 2002 1025 1029 (Pubitemid 35247310)
33. R.A. Kyle, S.P. Treon, R. Alexanian Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia Semin Oncol 30 2003 116 120 (Pubitemid 36506292)
34. M.A. Dimopoulos, M.A. Gertz, E. Kastritis Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia J Clin Oncol 27 2009 120 126
35. A. Biragyn, K. Tani, M.C. Grimm, S. Weeks, L.W. Kwak Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity Nat Biotechnol 17 1999 253 258 (Pubitemid 29122633)
36. E. Kimby, S.P. Treon, A. Agnanostopoulos Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia Clin Lymph Myeloma 6 2006 380 383